EpiPen Competitor Auvi-Q Re-Enters Market in February

Jan 20, 2017

CNBC

Virgina-based Kaleo Pharma will re-introduce its competitor to Mylan's EpiPen back to the market on February 14.

The list price for Kaleo's Auvi-Q is $4,500, but the drugmaker guarantees a cash price of no more than $360 for two auto-injectors.

Kaleo has said many insurers will cover the product. Additionally, the drugmaker will offer a program called "Auvi-Q AffordAbility" that guarantees U.S. patients with commercial insurance will have no out-of-pocket costs for the devices, plus free product for those who don't have insurance and have a household income of less than $100,000.

The Auvi-Q auto-injector was pulled from the market in 2015 when it was recalled in for inaccurate dosage delivery.

Read the CNBC coverage